Expanding the evidence base supporting shorter treatment durations for multidrug-resistant tuberculosis

International Journal of Tuberculosis and Lung Disease

Volumn 19, Issue 5, 2015, Pages 497-498

  Nuermberger, Eric ^a   Yew, Wing Wai ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; CLOFAZIMINE; DELAMANID; GATIFLOXACIN; ISONIAZID; LINEZOLID; PYRAZINAMIDE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; EVIDENCE BASED MEDICINE; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENCE RISK; SHORT COURSE THERAPY; SPUTUM CULTURE; THORAX RADIOGRAPHY; TREATMENT DURATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; MALE; MEDICATION COMPLIANCE; STATISTICS AND NUMERICAL DATA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84928879777     PISSN: 10273719     EISSN: 18157920     Source Type: Journal    
DOI: 10.5588/ijtld.15.0110     Document Type: Editorial

References (10)

1. Falzon D, Jaramillo E, Schunemann H J, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-528.
2. Chiang C-Y, Van Deun A, Enarson D A. A poor drug-resistant tuberculosis programme is worse than no programme: time for a change. Int J Tuberc Lung Dis 2013; 17: 714-718.
3. Van Deun A, Maaug A K, Salim M A, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182: 684-692.
4. Aung K J, Van Deun A, Declercq E, et al. Successful '9-month Bangladesh regimen' for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis 2014; 18: 1180-1187.
5. Yew W-W, Nuermberger E. High-dose fluoroquinolones in short-course regimens for treatment of MDR-TB: the way forward? Int J Tuberc Lung Dis 2013; 17: 853-854.
6. Kuaban C, Noeske J, Rieder H L, Aït-Khaled N, Abena Foe J-L, Trébucq A. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis 2015; 19: 000-000. [in this issue]
7. Leung E D, Yew W-W, Leung C C, Leung W M, Tam C M. Shorter treatment duration for selected patients with multidrug-resistant tuberculosis. Eur Repir J 2011; 38: 227-230.
8. Piubello A, Harouna S H, Souleymane M B, et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis 2014; 18: 1188-1194.
9. Chang K C, Leung C C, Yew W-W, et al. Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis. Antimicrob Agents Chemother 2012; 56: 5465-5475.
10. Heyckendorf J, Olaru I D, Ruhwald M, Lange C. Getting personal perspectives on individualized treatment duration in multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2014; 190: 374-383.